Clinical-stage gene therapy developer Genprex (GNPX)<\/strong> announced that new preclinical data from its lead drug candidate, REQORSA\u00ae (quaratusugene ozeplasmid)<\/strong>, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics<\/strong> later this month. The conference, a major global oncology event, is scheduled for October 22\u201326, 2025<\/strong> at the Hynes Convention Center in Boston, Massachusetts<\/strong>.<\/p>\n\n\n\n The data, generated in collaboration with Genprex\u2019s research partners, focuses on ALK-EML4 positive non-small cell lung cancer (NSCLC)<\/strong>\u2014a rare but aggressive form of lung cancer that primarily affects younger, non-smoking patients<\/strong>. According to the company, REQORSA demonstrated a strong pro-apoptotic effect<\/strong>, meaning it was able to trigger cancer cell death in preclinical models.<\/p>\n\n\n\n \u201cWe are thrilled that our collaborators have once again been selected to present positive preclinical data on the use of REQORSA,\u201d said Ryan Confer, President and CEO of Genprex<\/strong>. \u201cThese data further validate REQORSA as a potential treatment for many types of cancer, including this challenging subset of lung cancer. We look forward to advancing our studies of REQORSA in combination with ALK inhibitors.\u201d<\/p>\n\n\n\n The featured poster at the conference is titled:<\/p>\n\n\n\n \u201cQuaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies.\u201d<\/strong><\/p>\n<\/blockquote>\n\n\n\n REQORSA works by delivering a tumor suppressor gene known as TUSC2<\/strong>, which is often missing or inactivated in cancers. Unlike traditional gene therapies, Genprex uses a non-viral delivery platform<\/strong>, potentially reducing safety risks associated with viral vectors.<\/p>\n\n\n\n The news adds to growing momentum around Genprex\u2019s development pipeline, which also includes clinical trials evaluating REQORSA in combination with AstraZeneca\u2019s Tagrisso<\/strong> and Merck\u2019s Keytruda<\/strong> for other forms of lung cancer. Investors have viewed today\u2019s announcement as a positive validation signal<\/strong> for Genprex\u2019s platform technology and oncology strategy.<\/p>\n\n\n\n With gene therapy continuing to redefine cancer treatment possibilities, Genprex\u2019s upcoming presentation will be closely watched by researchers, biotech investors, and potential pharmaceutical partners seeking novel tumor-targeting strategies.<\/p>\n\n\n\n\n